Masofaniten is under clinical development by ESSA Pharma and currently in Phase I for Castration-Resistant Prostate Cancer (CRPC). According to GlobalData, Phase I drugs for Castration-Resistant Prostate Cancer (CRPC) have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Masofaniten’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Masofaniten overview

Masofaniten (EPI-7386) is under development for the treatment of metastatic castration resistant prostate cancer, metastatic hormone-sensitive prostate cancer and AR driven cancers. The drug candidate is administered through oral route. The drug candidate acts by targeting N-Terminus domain (NTD) of the androgen receptor. It was also under development for the treatment of breast cancer.

ESSA Pharma overview

ESSA Pharma is a drug developer that offers oncology therapeutics. The company’s pipeline products include EPI-506 in which it includes the programs 3rd-Generation AR N-terminal domain inhibitor, AR N-terminal domain, tau-1 site inhibitor, AR N-terminal, domain degrader among others. It offers clinical trials. The company has collaboration with the cancer prevention and research institute to advance science for cancer biology developments. It operates in Canada and the US. ESSA Pharma is headquartered in Vancouver, British Columbia, Canada.

For a complete picture of Masofaniten’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.